H.C. Wainwright assumed coverage of Cullinan Therapeutics (CGEM) with a Buy rating and $24 price target The company has the option to co-commercialize zipalertinib in the U.S. with Taiho and is also eligible to receive an additional $130M in regulatory milestones in connection with the agreement, the analyst tells investors in a research note. The firm sees several near-term catalysts for the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGEM:
- Cullinan has positive read from Novartis data, says Clear Street
- Promising Pipeline Developments and Strategic Collaborations Drive Buy Rating for Cullinan Management
- Cullinan Management’s Transition to Smaller Reporting Status: Balancing Reduced Disclosures and Investor Concerns
- Cullinan Therapeutics Reports Q2 2025 Financial Results
- Cullinan Management: Strong Financials and Promising Pipeline Justify Buy Rating